Article

Positron emission tomography imaging of platinum resistant ovarian cancer and drug modulation

2012-01-01

Abstract excerpt

Epithelial ovarian cancer is the commonest cause of death from gynaecological malignancy. Platinum based chemotherapy remains the cornerstone of first-line therapy for ovarian cancer, however relapse is common and acquired resistance is frequently observed on subsequent lines of platinum based treatment. Because activation of the PI3K/AKT pathway has been shown to play a role in acquired platinum resistance phenot...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8df0ee38-be1b-5bb3-aa96-ac3b51e53424
DOI: 10.25560/10532

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Positron emission tomography imaging of platinum resistant ovarian cancer and drug modulationDOI 10.25560/10532Read

The effect of AKT pathway inhibition on reversal of platinum resistance in ovarian cancer : a translational approachSemantic proximity Read

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Semantic proximity Read

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.Semantic proximity Read

Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian CancerSemantic proximity Read

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum ResistanceSemantic proximity Read

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitroSemantic proximity Read

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentSemantic proximity Read

A PET imaging agent for evaluating PARP-1 expression in ovarian cancerSemantic proximity Read

A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Safety, Tolerability, and Preliminary Efficacy AnalysisSemantic proximity Read

Paclitaxel and Its Evolving Role in the Management of Ovarian CancerSemantic proximity Read

The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancerSemantic proximity Read

Mechanistic basis of a combination d-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivoSemantic proximity Read